IP Library Granted Patent US 10,967,063
Granted Patent B2
US 10,967,063 · App. 16/019,623 · Granted Apr 6, 2021

Surfactant-free, water-free formable composition and breakable foams and their uses

Inventors: Dov Tamarkin (Ness Ziona, IL); Elana Gazal (Rehovot, IL); Irakliy Papiashvili (Ashkelon, IL); Yohan Hazot (Rehovot, IL); David Schuz (Gimzu, IL); Rita Keynan (Rehovot, IL)
Assignee: Vyne Therapeutics Inc.
A61K47/44A61K8/31A61K8/342A61K8/361A61K9/0014A61K9/0048A61K9/12A61K9/122A61K9/124A61K31/137A61K31/192A61K31/4164A61K31/57A61K31/573A61K31/593A61K31/65A61K45/06A61K47/02A61K47/06A61K47/10A61K47/12A61K47/24A61Q17/04A61Q19/00A61Q19/10A61K2800/31A61K2800/33
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,967,063
App. No.
16/019,623
Granted
Apr 6, 2021
Kind
B2
Abstract

A substantially surface active agent-free and foam adjuvant-free composition which includes a hydrophobic solvent, a wax and a propellant. A substantially surface active agent-free and foam adjuvant-free composition, further comprising, a tetracycline antibiotic, or one or more other active agents. A method of treatment, using a substantially surface active agent-free and substantially foam adjuvant-free composition.

Claims (19)

1. A method of treating acne vulgaris or rosacea, comprising administering a waterless foam composition free of surfactant and polymeric agent comprising

a tetracycline antibiotic and a foamable carrier,

the foamable carrier comprising:

a) about 50% to about 90% by weight of the foamable carrier of a liquid oil and about 10% to about 50% by weight of the foamable carrier of a paraffin wax selected from the group consisting of a paraffin wax having a melting point of 58-62° C., a paraffin wax having a melting point of 51-53° C. and a mixture thereof, wherein the total weight of the liquid oil and wax together is between about 85% and about 100% by weight of the foamable carrier; or

b) about 40% by weight of the foamable carrier of a liquid oil and about 60% by weight of the foamable carrier of a paraffin wax having a melting point of 42-44 c′C; and

a liquefied or compressed gas propellant; and

wherein the ratio of the foamable carrier to the propellant is from about 100:4 to about 100:25; and

wherein the composition is substantially free of a foam adjuvant.

2. The method of claim 1 , wherein the administered foam composition further comprises a second active agent.

3. The method of claim 1 , wherein the foamable carrier further comprises a second wax that has a melting point between about 47° C. and about 64° C. or wherein the second wax is selected from a hydrogenated castor oil, a beeswax, and a mixture thereof.

4. The method of claim 2 , wherein the second active agent is selected from the group consisting of an active herbal extract, an acaricide, an age spot and keratose removing agent, an allergen, an alpha hydroxyl acid, an analgesic agent, an antiacne agent, an antiallergic agent, an antiaging agent, an antibacterial agent, an antibiotic, an antiburn agent, an anticancer agent, an antidandruff agent, an antidepressant, an antidermatitis agent, an antiedemic agent, an antifungal agent, an antihistamine, an antihelminth agent, an antihyperkeratolyte agent, an anti-infective agent, an antiinflammatory agent, an antiirritant, an antilipemic agent, an antimicrobial agent, an antimycotic agent, an antioxidant, an antiparasitic agent, an antiproliferative agent, an antipruritic agent, an antipsoriatic agent, an antirosacea agent, an antiseborrheic agent, an antiseptic agent, an antiswelling agent, an antiviral agent, an anti-wart agent, an anti-wrinkle agent, an antiyeast agent, an astringent, a beta-hydroxy acid, benzoyl peroxide, a topical cardiovascular agent, a chemotherapeutic agent, a corticosteroid, an immunogenic substance, a dicarboxylic acid, a disinfectant, a fungicide, a hair growth regulator, a haptene, a hormone, a hydroxy acid, an immunosuppressant, an immunoregulating agent, an immunomodulator, an insecticide, an insect repellent, a keratolytic agent, a lactam, a local anesthetic agent, a lubricating agent, a masking agent, a metals, a metal oxide, a mitocide, a neuropeptide, a non-steroidal anti-inflammatory agent, an oxidizing agent, a pediculicide, a peptide, a protein, a photodynamic therapy agent, a radical scavenger, a refatting agent, a retinoid, a sanative, a scabicide, a self tanning agent, a skin protective agent, a skin whitening agent, a steroid, a steroid hormone, a vasoconstrictor, a vasodilator, a vitamin, a vitamin A, a vitamin A derivative, a vitamin B, a vitamin B derivative, a vitamin C, a vitamin C derivative, a vitamin D, a vitamin D derivative, a vitamin D analog, a vitamin F, a vitamin F derivative, a vitamin K, a vitamin K derivative, a wound healing agent and a wart remover, an androgen, an anti-hyperkeratosis agent, an estrogen, an immunestimulant, a pesticide, a progesterone, a sedative, a vaso active agent, and a mixture of any two or more thereof.

5. The method of claim 1 , wherein the tetracycline antibiotic is a minocycline or a doxycycline.

6. The method of claim 2 , wherein the second active agent is a retinoid.

7. The method of claim 1 , wherein the foamable carrier further comprises about 1% or less than 1% by weight of the foamable carrier of a foam adjuvant.

8. The method of claim 1 , wherein the composition is free of foam adjuvant.

9. The method of claim 1 , wherein the foamable carrier further comprises about 5% or less than 5% by weight of the foamable carrier of polyols.

10. The method of claim 1 , wherein the composition is free of short chain alcohols.

11. The method of claim 1 , further comprising a solid or semi-solid oil.

12. The method of claim 1 , wherein the composition is free of short chain alcohol and polyol.

Assignments (11)
SECURITY INTEREST Recorded Dec 28, 2023
From: JOURNEY MEDICAL CORPORATION; JG PHARMA, INC.
To: SWK FUNDING LLC
Reel/Frame 066157/0079 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 1, 2022
From: VYNE THERAPEUTICS INC.; VYNE PHARMACEUTICALS INC.
To: JOURNEY MEDICAL CORPORATION
Reel/Frame 058925/0568 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 22, 2021
From: VYNE THERAPEUTICS INC.
To: VYNE PHARMACEUTICALS INC.
Reel/Frame 058463/0167 →
RELEASE OF SECURITY INTEREST Recorded Sep 20, 2021
From: PERCEPTIVE CREDIT HOLDINGS II, LP
To: VYNE PHARMACEUTICALS LTD. (F/K/A FOAMIX PHARMACEUTICALS LTD.)
Reel/Frame 057544/0138 →
RELEASE OF SECURITY INTEREST Recorded Sep 20, 2021
From: PERCEPTIVE CREDIT HOLDINGS II, LP
To: VYNE THERAPEUTICS INC. (F/K/A MENLO THERAPEUTICS INC. AND SUCCESSOR-IN-INTEREST TO VYNE PHARMACEUTICALS LTD., F/K/A FOAMIX PHARMACEUTICALS LTD.)
Reel/Frame 057544/0708 →
PATENT SECURITY AGREEMENT Recorded Feb 17, 2021
From: VYNE THERAPEUTICS INC.
To: PERCEPTIVE CREDIT HOLDINGS II, LP
Reel/Frame 055326/0009 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 4, 2021
From: VYNE PHARMACEUTICALS LTD.
To: VYNE THERAPEUTICS INC.
Reel/Frame 055215/0298 →
CHANGE OF NAME Recorded Nov 4, 2020
From: FOAMIX PHARMACEUTICALS LTD.
To: VYNE PHARMACEUTICALS LTD.
Reel/Frame 054306/0387 →
PATENT SECURITY AGREEMENT Recorded Jul 30, 2019
From: FOAMIX PHARMACEUTICALS LTD
To: PERCEPTIVE CREDIT HOLDINGS II, LP
Reel/Frame 049912/0045 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 24, 2018
From: TAMARKIN, DOV; GAZAL, ELANA; PAPIASHVILI, IRAKLIY; HAZOT, YOHAN; SCHUZ, DAVID; KEYNAN, RITA
To: FOAMIX LTD.
Reel/Frame 046952/0316 →
CHANGE OF NAME Recorded Sep 24, 2018
From: FOAMIX LTD.
To: FOAMIX PHARMACEUTICALS, LTD.
Reel/Frame 047131/0710 →
Continuity (9)
Division 13499709
Provisional Application 61248144 · Oct 2, 2009
Provisional Application 61322148 · Apr 8, 2010
Provisional Application 61331126 · May 4, 2010
Provisional Application 61349911 · May 31, 2010
Provisional Application 61380568 · Sep 7, 2010
Provisional Application 61385385 · Sep 22, 2010
Provisional Application 61388884 · Oct 1, 2010
Related Publication 20190000980A1 · Jan 3, 2019
Cited By (1)
US 12,661,407